Chimeric Antigen Receptor T Cell-Related Neurotoxicity: Mechanisms, Clinical Presentation, and Approach to Treatment
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Chimeric Antigen Receptor T Cell-Related Neurotoxicity: Mechanisms, Clinical Presentation, and Approach to Treatment
Authors
Keywords
Chimeric antigen receptor T cell, Immune effector cell-associated neurotoxicity syndrome, Adoptive cell transfer, Cerebral edema, Blood-brain barrier
Journal
Current Treatment Options in Neurology
Volume 21, Issue 8, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-07-20
DOI
10.1007/s11940-019-0580-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
- (2018) Margherita Norelli et al. NATURE MEDICINE
- Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'
- (2018) David T. Teachey et al. Nature Reviews Clinical Oncology
- EEG findings in CAR T-cell therapy-related encephalopathy
- (2018) Aline Herlopian et al. NEUROLOGY
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)
- (2018) Bianca D. Santomasso et al. Cancer Discovery
- Chimeric Antigen Receptor T Cell–Mediated Neurotoxicity in Nonhuman Primates
- (2018) Agne Taraseviciute et al. Cancer Discovery
- The biological basis and clinical symptoms of CAR-T therapy-associated toxicites
- (2018) Aleksei Titov et al. Cell Death & Disease
- Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
- (2018) Juliane Gust et al. CNS DRUGS
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes
- (2017) Carlos A. Ramos et al. JOURNAL OF CLINICAL INVESTIGATION
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
- (2017) Terry J Fry et al. NATURE MEDICINE
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- (2017) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond
- (2017) ZeNan L. Chang et al. TRENDS IN MOLECULAR MEDICINE
- CNS Endothelial Cell Activation Emerges as a Driver of CAR T Cell–Associated Neurotoxicity
- (2017) Crystal L. Mackall et al. Cancer Discovery
- Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
- (2017) Juliane Gust et al. Cancer Discovery
- Beta-trace Protein as a new non-invasive immunological Marker for Quinolinic Acid-induced impaired Blood-Brain Barrier Integrity
- (2017) Andreas Baranyi et al. Scientific Reports
- Toxicities of chimeric antigen receptor T cells: recognition and management
- (2016) Jennifer N. Brudno et al. BLOOD
- Survival in adults with sickle cell disease in a high-income setting
- (2016) K. Gardner et al. BLOOD
- Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
- (2016) Chun-Meng Wang et al. CLINICAL CANCER RESEARCH
- CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies
- (2016) CJ Turtle et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Cytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction
- (2016) Hannah R. Wardill et al. INTERNATIONAL JOURNAL OF CANCER
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
- (2016) Cameron J. Turtle et al. JOURNAL OF CLINICAL INVESTIGATION
- Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents
- (2016) Ian A. Clark et al. Journal of Neuroinflammation
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cell signaling in NMDA preconditioning and neuroprotection in convulsions induced by quinolinic acid
- (2011) Patricia Cardoso Severino et al. LIFE SCIENCES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search